Safety, Usability, and Effectiveness of a Gait Exoskeleton for Children and Adolescents With Neurodevelopmental Disorders.

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age2-17
SponsorMarsiBionics

About this trial

Neurodevelopmental disorders often result in abnormal development of the Central Nervous System (CNS), frequently causing motor dysfunctions such as the inability to stand and walk. CLINICAL EXPLORER is a clinical-use robotic device for gait training, representing the evolution of the ATLAS 2030 exoskeleton and the EXPLORER device for home use. The aim of this study is to evaluate the safety and usability of CLINICAL EXPLORER .

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age between 2 and 17 years.

Consent from the participant or legal guardian to participate in the study.

No diagnosis of neurodevelopmental disorders such as CP, NMD, LM, or MS. Inclusion Criteria for Phase 1

Age between 2 and 17 years.

Disqualifiers

Any medical contraindication for standing or walking.

Presence of non-reducible contractures or heterotopic ossification above the degrees allowed by the device and/or outside the trajectory imposed by the device.

Spasticity (MAS) = 4 in lower limbs at the time of device use.

Structured hip and/or knee contracture greater than 20 degrees.

Trial design

Design model

Single group

Treatments tested in this trial

  • CLINICAL EXPLORER

    Device

    8 sessions of use of the device in the rehabilitation center

Treatment groups

60 Participants
are divided into 1 treatment group
Group A: CLINICAL EXPLORERExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Serious Adverse Events

occurrence of any serious adverse event to the participant or the caregiver

Time frame
through study completion, along 8 weeks
2

Falls prevalence

Number of falling events occurred from the participant or caregiver

Time frame
through study completion, along 8 weeks
3

Skin integrity

Occurrence of any injury of the skin in the areas of contact and produced by the use of the device

Time frame
through study completion, along 8 weeks
4

Pain (Visual Analogic Scale)

pain measured by the Visual Analogic Scale (VAS) by the participant and the caregiver, scored from 0 to 10, being 0 "no pain" and 10 "unbearable pain"

Time frame
through study completion, along 8 weeks

Secondary outcomes

1

Gait analysis

Spatiotemporal parameters will be done through photogrammetry.

Time frame
Day 1 and at the end of the intervention at 8 weeks
2

Range of motion

Passive Degree to which a joint can move (hip, knee, and ankle joints in both legs). From 0º to 180º.

Time frame
Day 1 and at the end of the intervention at 8 weeks
3

Quality of life (EQ-5D)

The EQ-5D is a standardized instrument used to measure and evaluate the quality of life. It assesses five key dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 3-level or 5-level scale, reflecting the severity of the condition (e.g., no problems, some problems, or extreme problems). The EQ-5D also includes a visual analogue scale (VAS) where individuals rate their overall health on a scale from 0 to 100. The tool is widely used in clinical trials, health surveys, and economic evaluations to assess health-related quality of life and make comparisons across different patient populations or interventions.

Time frame
Day 1 and at the end of the intervention at 8 weeks
4

Level of fatigue

Fatigue of both the participant and the therapist, Measured with the Borg scale

Time frame
through study completion, along 8 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

MarsiBionics

Lead sponsor

Hospital Infantil Universitario Niño Jesús, Madrid, Spain

Collaborator

APAC, I.A.P.

Collaborator

This trial is not recruiting at the moment. You can still explore other options: